Biotech & Pharma Updates | February 26 - March 3, 2026
🧬 Novo Nordisk commits $506M to upgrade Irish facility for oral Wegovy production ahead of European approval, Alveus Therapeutics raises $37M Series A extension for obesity drug development, Atrium Therapeutics spins out of Novartis-acquired Avidity with $270M to develop RNA medicines for rare heart diseases, Roche's fenebrutinib (BTK inhibitor) hits Ph3 goals in relapsing multiple sclerosis despite safety concerns, Sanofi + Sino Biopharmaceutical license JAK/ROCK inhibitor rovadicitinib globally, $135M upfront +$1.53B total, Earendil Labs + WuXi XDC partner on next-gen ADC linker technology + $885M total deal, Moderna's mCombriax combination flu and COVID-19 vaccine wins European drug regulators' positive recommendation for ages 50+
